WO2006022182A1 - 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 - Google Patents
2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 Download PDFInfo
- Publication number
- WO2006022182A1 WO2006022182A1 PCT/JP2005/015038 JP2005015038W WO2006022182A1 WO 2006022182 A1 WO2006022182 A1 WO 2006022182A1 JP 2005015038 W JP2005015038 W JP 2005015038W WO 2006022182 A1 WO2006022182 A1 WO 2006022182A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- phenylpiperazine
- cyanopyridine
- added
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a process for producing 2- (4-methyl-2-phenylbiperazine — 1-yl) -3-3-cyanopyridine. More specifically, the present invention relates to a process for producing 2- (4-methylthiol-2-phenylpiperazine 1_yl) 1-3-cianopyridine which can be suitably used as an intermediate for the production of mirtazapine useful as an antidepressant.
- Background art
- Mirtazapine is a useful compound as an antidepressant
- 2- (4-methyl-2_phenylpiperazine _ 1_yl) -3-cianopyridine is known as an intermediate for the production of mirtazapine.
- 2- (4-Methyl-2-phenylpiperazine _ 1 yl) 1 3-Cyanobilysine can be produced by using 1 _methyl _ 3-phenylpiperazine, 2-chloro-3-cyanopyridine and potassium fluoride.
- a method of reacting in the presence of is known (JP59-42678-B).
- the object of the present invention has been made in view of the above prior art, and does not use expensive fluorinated rhodium potassium iodide or the like, and is useful as an intermediate for producing mirtazapine.
- _Phenylpiperazine 1-yl) To provide a process that can easily and economically produce 3-cyanopyridine.
- the present invention is as follows.
- 1-cyanpyridine consists of 1-methyl-1-3-phenylpiperazine and 2-chloro-3-cyanpyridine in the presence of an organic base. And in the absence of an alkali metal halide, the reaction can be easily performed in a polar non-protonic organic solvent.
- 1-Methyl-3-phenylpiperazine is described in, for example, the method described in WO01 / 023345 Can be manufactured by the method.
- Commercially available 2-chiroguchi 3-3-canopyridine can be used.
- the amount of 1-methyl-1-3-phenylpiperazine is usually from 0.6 to 1 with respect to 1 mol of 2-chloro-3-cyanopyridine from the viewpoint of sufficiently proceeding with the reaction with 2-chloro-3-hydroxysilane. 1 mol, preferably 0.65 to 0.9 mol.
- organic base examples include alkylamines such as triethylamine and diisopropylethylamine; cyclic amines such as N-methylmorpholine; aromatic amines such as pyridine and picoline. Of these, triethylamine is preferred from the viewpoint of economy.
- the amount of base is 1 mole of 1-methyl-3-phenylpiperazine from the viewpoint of sufficient reaction of 1-methyl-1-phenylpiperazine and 2-chlorosilane-3cyanopyridine and economic efficiency. The amount is usually 1.1 to 2 mol, preferably 1.3 to 1.5 mol.
- Examples of the polar aprotic organic solvent include dimethylformamide, dimethylacetamide, dimethyl sulfoxide, 1,3-dimethylimidazolidin-2-one and the like.
- dimethylformamide can be preferably used from the viewpoint of economy.
- the amount of the solvent is not particularly limited, but is usually 100-500 parts by volume, preferably 150-400 parts by volume with respect to 100 parts by weight of 1-methyl-3-phenylbiperazine. It is.
- an appropriate amount of a quaternary ammonium salt such as tetraptylammonium iodide, tetraptylammonium bromide, benzyltrimethylammonium chloride, or the like may be used as a catalyst. Good.
- the reaction between 1-methyl-3-phenylbiperazine and 2_chloro-3-cyanpyridine is preferably carried out in an inert gas such as nitrogen gas or argon gas.
- an inert gas such as nitrogen gas or argon gas.
- 1-methyl-3-phenylpiperazine, 2-chloro-3-cyanopyridine and an organic base, and if necessary, a quaternary ammonium salt are mixed in a polar aprotic organic solvent under the inert gas atmosphere. Can be done.
- the reaction temperature is generally 90 to 160, preferably 110 to 150 ° (:, more preferably, from the viewpoint of improving the reaction rate and suppressing the formation of by-products. 1 1 0 to 1 30 ° C. Since the reaction time varies depending on the reaction temperature, it cannot be determined unconditionally, but it is usually about 12 to 30 hours.
- reaction solution has an internal temperature of 70 to 95 ° C and a degree of vacuum of 7 to 2.7 kPa
- 75 to 95% of the dimethylformamide used is distilled off, and 70 to 80 to 80 ° C.
- 100 to 2500 parts by weight of water are added to 100 parts by weight of 1-methyl-3-phenylpiperazine.
- pH is adjusted to 8-9 with alkali.
- alkali include sodium hydroxide and sodium carbonate.
- sodium hydroxide When sodium hydroxide is used as the Al force, it can usually be used as a 10 to 40% by weight sodium hydroxide aqueous solution.
- this reaction solution is extracted with a solvent such as ethyl acetate.
- ethyl acetate When ethyl acetate is used as a solvent, the amount used is usually 300 to 800 parts by weight per 100 parts by weight of 1-methyl-3-phenylpiperazine.
- the extraction temperature is preferably 40 to 50 ° C.
- the produced 2- (4-methyl-2-phenylpipera. Gin-11-yl) -1-3-cyanopyridine is dissolved in an organic solvent such as ethyl acetate, methanol or ethanol, and an acid is added thereto. After the addition, the crystals can be filtered and dried and isolated as a salt of 2_ (4-methyl-1-phenylbiperazine-11-yl) -1-3-cyanopyridine.
- organic acids such as succinic acid, succinic acid, maleic acid, methane sulfonic acid, and toluene sulfonic acid
- inorganic acids such as sulfuric acid, hydrochloric acid, and phosphoric acid
- oxalic acid is preferred from the viewpoints of crystallinity, purity and yield.
- this solution is cooled to 15 to 25 and aged for 1 to 10 hours, followed by filtration, and a mixed solvent of methanol and ethyl acetate (for example, ethyl acetate 3 parts by volume of methanol 3 parts by volume). ⁇ 4 volume parts).
- a mixed solvent of methanol and ethyl acetate for example, ethyl acetate 3 parts by volume of methanol 3 parts by volume. ⁇ 4 volume parts.
- 2- (4 1-methyl-2-phenylbiperazine 1-yl) 1 3-cyanopyridine succinate can be obtained by drying at a drying temperature of 50 to 60 ° C.
- 2- (4-Methyl-2-phenylpiperazine 1 1 yl) —3—Cyanopyridine or its fate is a useful compound as an intermediate for the production of milyuzapine.
- 2- (4-methyl-1-phenylpiperazine 1- 1yl) by the reaction of 1-methyl-3-phenylpiperazine with 2-chloro-3-pyridine.
- the rich compound can be obtained efficiently without using an alkali metal halide that has been an essential component in the production of cyanopyridine, and the yield of the target product can be expected to be higher than the conventional method.
- the present invention will be described in more detail based on examples, but the present invention is not limited to such examples.
- Mobile phase Liquid A Dissolve 0.05 mol of disodium hydrogen phosphate in 1 L of purified water and adjust to pH 6 with phosphoric acid.
- 2- (4-methyl-2-phenylbiperazine 1- 1yl) 1-3-cyanopyridine which is useful as an intermediate for the production of mill evening zapine, is compared with the conventional method. It can be advantageously obtained industrially.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005275935A AU2005275935A1 (en) | 2004-08-24 | 2005-08-11 | Method for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine |
CA002576299A CA2576299A1 (en) | 2004-08-24 | 2005-08-11 | Method for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine |
US11/660,645 US20080182987A1 (en) | 2004-08-24 | 2005-08-11 | Method For Producing 2-(4-Methyl-2-Phenylpiperazine-1-Yl)-3-Cyanopiridine |
EP05780394A EP1783125A4 (en) | 2004-08-24 | 2005-08-11 | PROCESS FOR THE PRODUCTION OF 2- (4-METHYL-2-PHENYLPIPERAZIN-1-YL) -3-CYANOPYRIDINE |
IL181075A IL181075A0 (en) | 2004-08-24 | 2007-01-30 | Process for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-243419 | 2004-08-24 | ||
JP2004243419 | 2004-08-24 | ||
JP2005-124722 | 2005-04-22 | ||
JP2005124722 | 2005-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006022182A1 true WO2006022182A1 (ja) | 2006-03-02 |
Family
ID=35967395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015038 WO2006022182A1 (ja) | 2004-08-24 | 2005-08-11 | 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080182987A1 (ja) |
EP (1) | EP1783125A4 (ja) |
AU (1) | AU2005275935A1 (ja) |
CA (1) | CA2576299A1 (ja) |
IL (1) | IL181075A0 (ja) |
WO (1) | WO2006022182A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103509000A (zh) * | 2013-10-21 | 2014-01-15 | 山东鲁药制药有限公司 | 一种药物中间体1-(3-氰甲基吡啶基-2)-4-甲基-2-苯基哌嗪的合成方法 |
CN109988148A (zh) * | 2018-01-02 | 2019-07-09 | 北京哈三联科技有限责任公司 | 1-(3-氰基吡啶-2)-2-苯基-4-甲基哌嗪草酸盐的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51122099A (en) * | 1975-04-05 | 1976-10-25 | Akzo Nv | Production of tetracyclic compound |
WO2001023345A1 (fr) * | 1999-09-30 | 2001-04-05 | Sumika Fine Chemicals Co., Ltd. | Procede de preparation de derive piperazine |
WO2002038552A1 (en) * | 2000-11-07 | 2002-05-16 | Sun Pharmaceutical Industries Ltd. | A novel method for the preparation of piperazine and its derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3049207A1 (de) * | 1980-12-27 | 1982-07-29 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue trisubstituierte pyrimido (5,4-d) pyrimidine, ihre herstellung und ihre verwendung als arzneimittel |
-
2005
- 2005-08-11 EP EP05780394A patent/EP1783125A4/en not_active Withdrawn
- 2005-08-11 WO PCT/JP2005/015038 patent/WO2006022182A1/ja active Application Filing
- 2005-08-11 AU AU2005275935A patent/AU2005275935A1/en not_active Abandoned
- 2005-08-11 US US11/660,645 patent/US20080182987A1/en not_active Abandoned
- 2005-08-11 CA CA002576299A patent/CA2576299A1/en not_active Abandoned
-
2007
- 2007-01-30 IL IL181075A patent/IL181075A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51122099A (en) * | 1975-04-05 | 1976-10-25 | Akzo Nv | Production of tetracyclic compound |
WO2001023345A1 (fr) * | 1999-09-30 | 2001-04-05 | Sumika Fine Chemicals Co., Ltd. | Procede de preparation de derive piperazine |
WO2002038552A1 (en) * | 2000-11-07 | 2002-05-16 | Sun Pharmaceutical Industries Ltd. | A novel method for the preparation of piperazine and its derivatives |
Non-Patent Citations (1)
Title |
---|
See also references of EP1783125A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2005275935A1 (en) | 2006-03-02 |
EP1783125A1 (en) | 2007-05-09 |
IL181075A0 (en) | 2007-07-04 |
US20080182987A1 (en) | 2008-07-31 |
EP1783125A4 (en) | 2008-06-18 |
CA2576299A1 (en) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5161023B2 (ja) | ピペラジン誘導体の製造方法 | |
CA2581835C (en) | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide | |
CA2988594C (en) | Methods of making protein deacetylase inhibitors | |
RU2621725C2 (ru) | Способ получения 1-([1,3]диоксолан-4-илметил)-1н-пиразол-3-иламина | |
WO2015124764A1 (en) | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate | |
EP2590947A1 (en) | Intermediates and process for preparing a thrombin specific inhibitor | |
WO2006022182A1 (ja) | 2-(4-メチル-2-フェニルピペラジン-1-イル)-3-シアノピリジンの製造方法 | |
JP2011506284A (ja) | 5−(2−エチルジヒドロ−1h−インデン−2−イル)−1h−イミダゾール及びその塩の調製方法 | |
JP4848704B2 (ja) | 2−(4−メチル−2−フェニルピペラジン−1−イル)−3−シアノピリジンの製造方法 | |
US8815870B2 (en) | 4-(2-(6-substituted-hexylidene) hydrazinyl)benzonitrile and preparation thereof | |
JP2001515496A (ja) | 5−アミノメチル−クロロピリジン類の製造方法 | |
PL173450B1 (pl) | Sposób wytwarzania podstawionych imidazoli | |
CN113214142B (zh) | 一种阿哌沙班的中间体及制备方法 | |
US20070037854A1 (en) | Process for preparing sulfonamide-containing indole compounds | |
EP1907360A1 (en) | Improved process for the manufacture of flecainide | |
US7214796B2 (en) | Process for production of 1-[2-(benzimidazol-2-yl-thio)ethyl]piperazine or salts thereof | |
CN114560862A (zh) | 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法 | |
JP5088893B2 (ja) | ピペリジン−4−オン誘導体の製造方法 | |
KR101325589B1 (ko) | 1-알킬-2-(2-아미노에틸)피롤리딘의 제조방법 | |
CN117843613A (zh) | 达比加群酯中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 181075 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005780394 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2576299 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11660645 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005275935 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005275935 Country of ref document: AU Date of ref document: 20050811 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005275935 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005780394 Country of ref document: EP |